Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVR1 | Q04771 | 13/20 | 0.64 |
| ▸ | RIPK2 | O43353 | 11/20 | 0.64 |
| ▸ | NOD2 | Q9HC29 | 11/20 | 0.64 |
| ▸ | TGFBR1 | P36897 | 5/20 | 0.45 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.39 |
| ▸ | FYN | P06241 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21630442 | 0.91 | NOD2 (0.54) | ACVR1RIPK2NOD2TGFBR1MAP4K1 | |
| SCHEMBL20523500 | 0.91 | ACVR1 (0.62) | ACVR1RIPK2NOD2TGFBR1MAP4K1 | |
| SCHEMBL21630382 | 0.89 | NOD2 (0.63) | ACVR1RIPK2NOD2TGFBR1TP53 | |
| SCHEMBL21630387 | 0.89 | ACVR1 (0.51) | ACVR1RIPK2NOD2TGFBR1FYN | |
| SCHEMBL21630433 | 0.87 | NOD2 (0.65) | ACVR1RIPK2NOD2TGFBR1 | |
| SCHEMBL20523519 | 0.78 | ACVR1 (1.00) | ACVR1RIPK2NOD2TGFBR1FYN | |
| SCHEMBL20523524 | 0.78 | ACVR1 (1.00) | ACVR1RIPK2NOD2TGFBR1 | |
| SCHEMBL20523534 | 0.76 | NOD2 (0.82) | ACVR1RIPK2NOD2TGFBR1 | |
| SCHEMBL20523650 | 0.75 | KMT2A (0.47) | ACVR1TGFBR1FYNMAPT | |
| SCHEMBL20523655 | 0.73 | RIPK2 (0.46) | ACVR1RIPK2NOD2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11135209-B2 | Compositions and methods for inhibiting protein kinases | UNIVERSITY OF HOUSTON SYSTEM (US) | 2021-10-05 | — | — | US | disclosed |
| EP-3600307-B1 | COMPOSITIONS FOR USE IN METHODS OF INHIBITING PROTEIN KINASES | UNIV HOUSTON SYSTEM (US) | 2021-05-05 | — | — | EP | disclosed |
| US-20200030303-A1 | COMPOSITIONS AND METHODS FOR INHIBITING PROTEIN KINASES | UNIVERSITY OF HOUSTON SYSTEM (US) | 2020-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11135209-B2 | Compositions and methods for inhibiting protein kinases | RIPK2, RIPK1, NOD2 | ACVR1 8/4885RIPK2 1/4885NOD2 3/4885 |
| US-20200030303-A1 | COMPOSITIONS AND METHODS FOR INHIBITING PROTEIN KINASES | RIPK2, RIPK1, NOD2 | ACVR1 8/4885RIPK2 1/4885NOD2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.